162 related articles for article (PubMed ID: 22296682)
1. Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.
Qin W; Gui G; Zhang K; Twelves D; Kliethermes B; Sauter ER
BMC Cancer; 2012 Feb; 12():52. PubMed ID: 22296682
[TBL] [Abstract][Full Text] [Related]
2. Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.
Deutscher SL; Dickerson M; Gui G; Newton J; Holm JE; Vogeltanz-Holm N; Kliethermes B; Hewett JE; Kumar SR; Quinn TP; Sauter ER
BMC Cancer; 2010 Oct; 10():519. PubMed ID: 20920311
[TBL] [Abstract][Full Text] [Related]
3. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Qin W; Zhu W; Wagner-Mann C; Folk W; Sauter ER
Cancer J; 2003; 9(4):293-301. PubMed ID: 12967140
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Jelisavac-Cosic S; Sirotkovic-Skerlev M; Kulic A; Jakic-Razumovic J; Kovac Z; Vrbanec D
Tumori; 2011; 97(4):532-9. PubMed ID: 21989445
[TBL] [Abstract][Full Text] [Related]
5. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
6. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Qin W; Zhu W; Wagner-Mann C; Sauter ER
Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Pusina S
Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N; Kates RE; Schmitt M
J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
[TBL] [Abstract][Full Text] [Related]
11. Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1.
Ettl J; Klein E; Hapfelmeier A; Grosse Lackmann K; Paepke S; Petry C; Specht K; Wolff L; Höfler H; Kiechle M
PLoS One; 2017; 12(9):e0183917. PubMed ID: 28877230
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
13. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
14. uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
Qin W; Zhu W; Hewett JE; Rottinghaus G; Chen YC; Flynn JT; Kliethermes B; Mannello F; Sauter ER
BMC Cancer; 2008 Oct; 8():298. PubMed ID: 18922176
[TBL] [Abstract][Full Text] [Related]
15. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
J Clin Oncol; 1999 Oct; 17(10):3048-57. PubMed ID: 10506599
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Grøndahl-Hansen J; Hilsenbeck SG; Christensen IJ; Clark GM; Osborne CK; Brünner N
Breast Cancer Res Treat; 1997 Apr; 43(2):153-63. PubMed ID: 9131271
[TBL] [Abstract][Full Text] [Related]
17. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
[TBL] [Abstract][Full Text] [Related]
19. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
[TBL] [Abstract][Full Text] [Related]
20. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
